ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Animals
Benzamides
/ pharmacology
Cell Line, Tumor
Cell Proliferation
Disease Models, Animal
Drug Resistance, Neoplasm
Epithelial Cells
/ pathology
Humans
Lung Neoplasms
/ drug therapy
MAP Kinase Signaling System
Mesoderm
/ pathology
Mice
MicroRNAs
/ genetics
Mitogen-Activated Protein Kinase Kinases
/ antagonists & inhibitors
Mutation
/ genetics
Neoplasms
/ drug therapy
Phosphorylation
/ drug effects
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins p21(ras)
/ genetics
Pyrimidines
/ pharmacology
Receptors, Interleukin-17
/ metabolism
Zinc Finger E-box-Binding Homeobox 1
/ metabolism
Journal
Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086
Informations de publication
Date de publication:
13 03 2019
13 03 2019
Historique:
received:
03
10
2017
revised:
20
08
2018
accepted:
18
02
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
23
2
2020
Statut:
ppublish
Résumé
Mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors have failed to show clinical benefit in Kirsten rat sarcoma (
Identifiants
pubmed: 30867319
pii: 11/483/eaaq1238
doi: 10.1126/scitranslmed.aaq1238
pmc: PMC6878763
mid: NIHMS1058166
pii:
doi:
Substances chimiques
Benzamides
0
KRAS protein, human
0
MIRN200 microRNA, human
0
MicroRNAs
0
Protein Kinase Inhibitors
0
Pyrimidines
0
Receptors, Interleukin-17
0
ZEB1 protein, human
0
Zinc Finger E-box-Binding Homeobox 1
0
mocetinostat
A6GWB8T96J
Mitogen-Activated Protein Kinase Kinases
EC 2.7.12.2
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA214609
Pays : United States
Informations de copyright
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
Cancer Cell. 2009 Jun 2;15(6):489-500
pubmed: 19477428
Cancer Cell. 2014 May 12;25(5):697-710
pubmed: 24746704
Nat Methods. 2007 Oct;4(10):847-9
pubmed: 17828270
Cancer Res. 2006 Jan 15;66(2):944-50
pubmed: 16424029
Br J Cancer. 2005 Jan 17;92(1):131-9
pubmed: 15597105
Cell Rep. 2012 Apr 19;1(4):385-91
pubmed: 22570807
Cell Rep. 2016 Jun 28;16(1):133-147
pubmed: 27320920
Nat Commun. 2014 Oct 28;5:5241
pubmed: 25348003
Nat Commun. 2016 Jul 26;7:12231
pubmed: 27456471
Genes Dev. 2009 Sep 15;23(18):2140-51
pubmed: 19759262
J Clin Oncol. 2010 Feb 10;28(5):744-52
pubmed: 20038723
Clin Cancer Res. 2015 Aug 1;21(15):3480-91
pubmed: 25878335
FEBS J. 2009 Feb;276(4):1024-35
pubmed: 19154344
J Biol Chem. 2003 Apr 18;278(16):14087-91
pubmed: 12604616
Cancer Res. 2007 May 15;67(10):4933-9
pubmed: 17510423
Sci Rep. 2016 Jan 05;6:18652
pubmed: 26728244
Nat Rev Drug Discov. 2014 Nov;13(11):828-51
pubmed: 25323927
J Clin Invest. 2012 Sep;122(9):3170-83
pubmed: 22850877
Nat Genet. 2015 May;47(5):539-43
pubmed: 25822087
Int J Cancer. 2017 Apr 15;140(8):1881-1887
pubmed: 28073170
JAMA. 2017 May 9;317(18):1844-1853
pubmed: 28492898
Nat Protoc. 2009;4(7):1064-72
pubmed: 19561589
J Cell Biochem. 2016 Oct;117(10):2346-56
pubmed: 26950413
Nature. 2012 Mar 18;483(7391):613-7
pubmed: 22425996
Mol Cell. 2003 May;11(5):1389-96
pubmed: 12769861
Cancer Discov. 2016 Jul;6(7):754-69
pubmed: 27154822
Nat Cell Biol. 2017 May;19(5):518-529
pubmed: 28414315
Nat Cell Biol. 2009 Dec;11(12):1487-95
pubmed: 19935649
Gut. 2012 Mar;61(3):439-48
pubmed: 22147512
J Med Chem. 2013 Jul 11;56(13):5219-30
pubmed: 23566315
FEBS J. 2015 Jan;282(1):32-53
pubmed: 25333451
Nature. 2016 Jun 30;534(7609):647-51
pubmed: 27338794
N Engl J Med. 2011 Mar 10;364(10):947-55
pubmed: 21388312
Oncogene. 2007 May 14;26(22):3203-13
pubmed: 17496916
Cell Rep. 2014 Apr 10;7(1):86-93
pubmed: 24685132
Development. 2013 Aug;140(16):3348-59
pubmed: 23863486
Ann Oncol. 2015 May;26(5):894-901
pubmed: 25722381
J Clin Invest. 2014 Jun;124(6):2696-708
pubmed: 24762440
J Clin Invest. 2016 Sep 1;126(9):3219-35
pubmed: 27500490
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Oncogene. 2017 Apr 6;36(14):1925-1938
pubmed: 27694892
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Oncogene. 2016 Jan 14;35(2):173-86
pubmed: 25798833
Clin Proteomics. 2010 Dec;6(4):129-51
pubmed: 21691416
Nat Rev Cancer. 2010 Apr;10(4):241-53
pubmed: 20300105
Curr Opin Genet Dev. 2009 Feb;19(1):4-11
pubmed: 19201597
Cancer Res. 2008 Jan 15;68(2):537-44
pubmed: 18199550
Clin Cancer Res. 2013 Jan 1;19(1):279-90
pubmed: 23091115
Nat Cell Biol. 2008 May;10(5):593-601
pubmed: 18376396
Nat Cell Biol. 2002 Feb;4(2):165-9
pubmed: 11802164
N Engl J Med. 2008 Sep 25;359(13):1367-80
pubmed: 18815398
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cancer Cell. 2006 Dec;10(6):459-72
pubmed: 17157787
EMBO Mol Med. 2015 Apr 14;7(6):831-47
pubmed: 25872941
Cancer Res. 1992 May 1;52(9 Suppl):2665s-2669s
pubmed: 1562997
Mol Biol Cell. 2011 May 15;22(10):1686-98
pubmed: 21411626
Nat Methods. 2009 Aug;6(8):569-75
pubmed: 19644458
Nat Cell Biol. 2002 Feb;4(2):170-4
pubmed: 11802165
J Thorac Oncol. 2009 Dec;4(12):1455-65
pubmed: 20009910
Cell Signal. 2008 Mar;20(3):518-33
pubmed: 18096367
Cancer Cell. 2014 Aug 11;26(2):207-21
pubmed: 25065853